CDH13, cadherin 13, 1012

N. diseases: 205; N. variants: 47
Disease: Colorectal Carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 PosttranslationalModification disease BEFREE In this study, we aimed to evaluate the association between T-cadherin promoter methylation and CRC by performing a meta-analysis. 28647701 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 PosttranslationalModification disease BEFREE CDH13 promoter methylation had a significantly increased risk for poorly differentiated CRC (OR = 4.07, P = 0.001). 28121942 2017
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 Biomarker disease BEFREE In addition, the interaction between CDH13 and the adiponectin gene (APN) for CRC risk was investigated using a logistic regression analysis. 26362652 2015
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 Biomarker disease BEFREE In conclusion, we found CDH13 and FBLN3 gene methylation are potential biomarkers for poor prognosis in CRC. 21796503 2012
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 Biomarker disease BEFREE Aberrant methylation of HLTF, SOCS-1, and CDH13 genes is shown in colorectal cancers without lymph node metastasis. 15793636 2005
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 PosttranslationalModification disease BEFREE We found a significant difference in histology (P=0.0053) when we compared the CDH13 methylation of poorly differentiated colorectal cancers to that of differentiated ones. 14997203 2004
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 GeneticVariation disease BEFREE The rest changed greatly in the methylation pattern in colorectal cancer (CRC): cyclin A1 (cyclin a1) (100%, 65/65), caudal type homeobox transcription factor 1 (CDX1) (100%, 65/65), RAR- (85%, 55/65), myogenic factor 3 (MYOD1) (69%, 45/65), cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (p15(INK4b)) (68%, 44/65), prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (COX2) (72%, 47/65), cadherin 13, H-cadherin (heart) (CDH13) (65%, 42/65), CAAX box 1 (CXX1) (58%, 38/65), tumor protein p73 (p73) (63%, 41/65) and Wilms tumor 1 (WT1) (58%, 38/65). 15526363 2004
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.080 PosttranslationalModification disease BEFREE Here we confirmed the promoter activity of 5' region of CDH13 by luciferase assay and examined its aberrant methylation in colorectal cancers, cell lines, and adenomas. 12067979 2002